Part I: Introduction
1 Basic Principles of Pharmacology
2 Principles for Maximizing the Safety of Dermatologic Drug Therapy
3 Polymorphisms: Why Individual Drug Responses Vary
4 Adherence to Drug Therapy
5 Medical Decision Making
Part II: Important Drug Regulatory Issues
6 The FDA Drug Approval Process
7 Pharmacovigilance: Verifying that Drugs Remain Safe
8 Drugs Taken Off the Market: Important Lessons Learned
Part III: Systemic Drugs for Infectious Diseases
9 Systemic Antibacterial Agents
10 Systemic Antifungal Agents
11 Systemic Antiviral Agents
12 Systemic Antiparasitic Agents
Part IV: Systemic Immunomodulatory Drugs
13 Systemic Corticosteroids
14 Methotrexate
15 Azathioprine
16 Mycophenolates
17 Cyclosporine
18 Phosphodiesterase-4 and Janus Kinase Inhibitors
19 Cytotoxic Agents
20 Dapsone
21 Antimalarial Agents
22 Systemic Retinoids
Part V: Drugs Used in Conjunction with UV or Visible Light
23 Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy
Modalities
24 Extracorporeal Photochemotherapy (Photopheresis)
25 Photodynamic Therapy
Part VI: Biologic Therapeutics
26 Tumor Necrosis Factor Inhibitors
27 Interleukin 12/23 Inhibitors
28 Interleukin 17 Inhibitors
29 Interleukin 23 Inhibitors
30 Rituximab
31 Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others
Part VII: Miscellaneous Systemic Drugs
32 Antihistamines
33 Vasoactive and Antiplatelet Agents
34 Antiandrogens and Androgen Inhibitors
35 Psychotropic Agents
36 Intravenous Immunoglobulin Therapy
37 Systemic Anticancer Agents: Dermatologic Indications and Adverse Events
38 Hedgehog Pathway Inhibitors
39 Drugs for the Skinternist
40 Miscellaneous Systemic Drugs
Part VIII: Topical Drugs for Infectious Diseases
41 Topical Antibacterial Agents
42 Topical Antifungal Agents
43 Topical and Intralesional Antiviral Agents
44 Topical Antiparasitic Agents
Part IX: Topical Immunomodulatory Drugs
45 Topical Corticosteroids
46 Topical Retinoids
47 Topical and Intralesional Chemotherapeutic Agents
48 Topical Calcineurin Inhibitors
49 Topical Vitamin D3
Part X: Miscellaneous Topical Drugs
50 Sunscreens
51 Therapeutic Shampoos
52 a-Hydroxy Acids
53 Chemical Peels
54 Products for the Care of Chronic Wounds
55 Agents Used for Treatment of Hyperkeratosis
56 Irritants and Allergens: When to Suspect Topical Therapeutic Agents
57 Miscellaneous Topical Agents
Part XI: Injectable and Mucosal Routes of Drug Administration
58 Local Anesthetics
59 Injectable Dermal and Subcutaneous Fillers
60 Botulinum Toxin Injections
61 Oral Mucosal Therapeutics
Part XII: Major Adverse Effects From Systemic Drugs
62 Hepatotoxicity of Dermatologic Drug Therapy
63 Hematologic Toxicity of Drug Therapy
64 Drug-induced Malignancy
65 Dermatologic Drugs During Pregnancy and Lactation
66 Drug Interactions
67 Cutaneous Drug Reactions With Systemic Features
Part XIII: Special Pharmacology and Therapeutics Topics
68 Informed Consent and Risk Management
69 Compounding in Dermatology
70 Dermatologic Drug Therapy in Children
Appendix I Core Questions for Understanding Systemic Dermatologic Drugs
Appendix II The Most Potentially Serious Drug Interactions
